Profile: EMA's Mentzer On Getting The Right Data and National Service
This article was originally published in Scrip
Executive Summary
Dirk Mentzer is chair of the European Medicines Agency's Paediatric Committee (PDCO), which assesses and adopts opinions on the pediatric investigation plans that your company must submit with most new marketing authorization applications. After an impressive career as a pediatrician, Mentzer joined Germany's Paul-Ehrlich-Institut where he is also head of pharmacovigilance for vaccine and biomedicinal products. He talked to Scrip about getting the full picture from companies, building go karts and being a sandwich child.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.